Sign in Subscribe
Associations

FDA Clears First Blood Test for Alzheimer's Disease Diagnosis

Strategic Insights

— 2 min read

A significant breakthrough in the diagnosis of Alzheimer's disease has been achieved with the approval of the first blood test by the U.S. Food and Drug Administration (FDA). The test, known as the Lumipulse G pTau217/ss-Amyloid 1-42 Plasma Ratio, detects amyloid plaques, a hallmark of Alzheimer's disease, through a blood draw, making it less invasive than other commonly used diagnostic tools. This development is expected to make diagnosis easier and more accurate for Americans, particularly with the interest in early diagnosis and treatment highlighted in the 2025 Alzheimer's Disease Facts and Figures special report.

Key Takeaways:

  • The FDA has approved the first blood test for the diagnosis of Alzheimer's disease, which detects amyloid plaques through a blood draw.
  • The test, Lumipulse G pTau217/ss-Amyloid 1-42 Plasma Ratio, is intended for adult patients aged 55 years and older exhibiting signs and symptoms of the disease.
  • Blood tests have been used in clinical trials for many years and are increasingly being used in clinical settings, often as a first-pass detection tool followed by additional testing.
  • The Alzheimer's Association is leading the development of clinical practice guidelines for the use of blood biomarker tests in specialty care settings, which will be debuted at the Alzheimer's Association International Conference (AAIC) in July.
  • Nearly 4 in 5 Americans would want to know if they had Alzheimer's disease before it impacted their lives, with 91% saying they would take a simple test if available, primarily for early treatment and care.
  • The approval of the blood test is a significant step toward better diagnosis and eventual treatment of Alzheimer's disease, made possible by historic investment in Alzheimer's and dementia research by the National Institutes of Health (NIH), the Alzheimer's Association, and other private entities.
  • Maria C. Carillo, Ph.D., Alzheimer's Association chief science officer and medical affairs lead, emphasizes the importance of considering who should be tested and when, and the need for evidence-based recommendations for specialists.

Statistics:

  • 91% of Americans say they would take a simple test, such as a blood biomarker test, if available, primarily for early treatment and care.
  • Nearly 4 in 5 Americans would want to know if they had Alzheimer's disease before it impacted their lives.
  • The 2025 Alzheimer's Disease Facts and Figures special report emphasizes the importance of early diagnosis and treatment.

Sources:

  • FDA News Release: "FDA Clears First Blood Test for Alzheimer's Disease"
  • Alzheimer's Association Press Release: "Statement on FDA Approval of First Blood Test for Alzheimer's Disease"
  • 2025 Alzheimer's Disease Facts and Figures special report
  • National Institutes of Health (NIH)

Read more